153 related articles for article (PubMed ID: 35366967)
1. Systemic Therapy for Vascular Anomalies and the Emergence of Genotype-Guided Management.
Nicholson CL; Maguiness SM
Dermatol Clin; 2022 Apr; 40(2):127-136. PubMed ID: 35366967
[TBL] [Abstract][Full Text] [Related]
2. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Shimano KA; Eng W; Adams DM
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29603. PubMed ID: 35253343
[TBL] [Abstract][Full Text] [Related]
3. Genetic Basis and Therapies for Vascular Anomalies.
Queisser A; Seront E; Boon LM; Vikkula M
Circ Res; 2021 Jun; 129(1):155-173. PubMed ID: 34166070
[TBL] [Abstract][Full Text] [Related]
4. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
5. Development of Molecular Therapies for Venous Malformations.
Kangas J; Nätynki M; Eklund L
Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():6-19. PubMed ID: 29668117
[TBL] [Abstract][Full Text] [Related]
6. Medical management of vascular anomalies.
Trenor CC
Semin Cutan Med Surg; 2016 Sep; 35(3):177-81. PubMed ID: 27607327
[TBL] [Abstract][Full Text] [Related]
7. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
Geeurickx M; Labarque V
J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review.
Freixo C; Ferreira V; Martins J; Almeida R; Caldeira D; Rosa M; Costa J; Ferreira J
J Vasc Surg; 2020 Jan; 71(1):318-327. PubMed ID: 31676179
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus for the treatment of children with various complicated vascular anomalies.
Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin and treatment of venous malformations.
Seront E; Van Damme A; Boon LM; Vikkula M
Curr Opin Hematol; 2019 May; 26(3):185-192. PubMed ID: 30855337
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in the Treatment of Vascular Anomalies.
Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
[No Abstract] [Full Text] [Related]
12. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase: a new kid on the block in vascular anomalies.
Castillo SD; Vanhaesebroeck B; Sebire NJ
J Pathol; 2016 Dec; 240(4):387-396. PubMed ID: 27577520
[TBL] [Abstract][Full Text] [Related]
14. Effects of sirolimus in the treatment of unresectable infantile hemangioma and vascular malformations in children: A single-center experience.
Cho YJ; Kwon H; Kwon YJ; Kim SC; Kim DY; Namgoong JM
J Vasc Surg Venous Lymphat Disord; 2021 Nov; 9(6):1488-1494. PubMed ID: 33836285
[TBL] [Abstract][Full Text] [Related]
15. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
Adams DM; Ricci KW
Hematol Oncol Clin North Am; 2019 Jun; 33(3):455-470. PubMed ID: 31030813
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus for management of complex vascular anomalies - A proposed dosing regimen for very young infants.
Czechowicz JA; Long-Boyle JR; Rosbe KW; Mathes EF; Frieden IJ; Shimano KA
Int J Pediatr Otorhinolaryngol; 2018 Feb; 105():48-51. PubMed ID: 29447818
[TBL] [Abstract][Full Text] [Related]
17. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
[TBL] [Abstract][Full Text] [Related]
18. Practical Genetic and Biologic Therapeutic Considerations in Vascular Anomalies.
Adams DM
Tech Vasc Interv Radiol; 2019 Dec; 22(4):100629. PubMed ID: 31864536
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and absorption of topical sirolimus for the treatment of vascular anomalies in children: A case series.
Le Sage S; David M; Dubois J; Powell J; McCuaig CC; Théorêt Y; Kleiber N
Pediatr Dermatol; 2018 Jul; 35(4):472-477. PubMed ID: 29790593
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus for the treatment of complicated vascular anomalies in children.
Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
